TP53 and cancer: The mutation panel used in our study was designed specifically for gynecological malignancies[16] based on previously reported mutations in gynecological tumors, giving a more precise overview of mutations compared to studies using generic cancer gene panels.[14,28] However, because of the mass spectrometric method we used, only “hot-spot” mutations were included in the panel, with which high coverage could be achieved.[16] Mutations in TP53 were not included in this study, and therefore 34% of somatic mutations in this cohort is likely an underestimation.